Why has ResMed rocketed up and is the ride over?

In our latest podcast episode, discover insights on ResMed's stock analysis and the impact of Ozempic and GLP-1 drugs with Senior Equity...

Look beyond market darlings for AI winners

AI has easily been the hottest topic in investing this year. While IML's Daniel Moore is excited about its potential, he is cautious of...

Podcast: Small-cap update – March quarter 2024

Simon Conn and Jason Guthrie discuss how the small-mid cap funds performed during the March quarter 2024 including key...

Podcast: Large-cap update – March quarter 2024

In our new podcast, Daniel Moore talks to Jason Guthrie about how IML's large-cap funds performed during March quarter...

Webinar series: A stock pickers market – quality & value still on offer

The IML investment team will feature in two upcoming webinars,...